Jessica Mann
Plus aucun poste en cours
Profil
Jessica Mann was the founder of Antidote Technologies, Inc. which was founded in 2010 where she held the title of Chief Medical Advisor.
She also held former positions at Novartis AG as a Principal, National Institutes of Health as a Cardiologist, Speedel Holding AG as a Principal, Lifearc as a Trustee, Evolva SA as a Chief Medical Officer from 2009 to 2010, and Sanifit Therapeutics SA as a Chief Medical Officer.
Dr. Mann received a doctorate degree from St. George's University of London.
Anciens postes connus de Jessica Mann
| Sociétés | Poste | Fin |
|---|---|---|
Lifearc
 Lifearc Miscellaneous Commercial ServicesCommercial Services Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 02/09/2019 |
Evolva SA
 Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Directeur Technique/Scientifique/R&D | 31/07/2010 |
Sanifit Therapeutics SA
 Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Directeur Technique/Scientifique/R&D | - |
Speedel Holding AG
 Speedel Holding AG Pharmaceuticals: MajorHealth Technology Speedel Holding operates as a holding company with interests in pharmaceutical manufacturing. The company was founded on July 19, 2000 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Antidote Technologies, Inc.
 Antidote Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Antidote Technologies, Inc. provides online search and referral engine for clinical trials. The firm transforms clinical trials by directly connecting patients with research organizations to make new treatments available. It provides clinical trials information in the areas of Alzheimer's, asthma, bipolar, breast cancer, COPD, depression, diabetes, HIV, leukemia, lung and prostate cancer & rheumatoid arthritis. The company was founded by Jessica Mann, Pablo Graiver and Eithan Ephrati in 2010 and is headquartered in London, the United Kingdom. | Fondateur | - |
Formation de Jessica Mann
| St. George's University of London | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Entreprise privées | 6 |
|---|---|
Evolva SA
Evolva SA Miscellaneous Commercial ServicesCommercial Services Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers. | Commercial Services |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
Antidote Technologies, Inc.
Antidote Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Antidote Technologies, Inc. provides online search and referral engine for clinical trials. The firm transforms clinical trials by directly connecting patients with research organizations to make new treatments available. It provides clinical trials information in the areas of Alzheimer's, asthma, bipolar, breast cancer, COPD, depression, diabetes, HIV, leukemia, lung and prostate cancer & rheumatoid arthritis. The company was founded by Jessica Mann, Pablo Graiver and Eithan Ephrati in 2010 and is headquartered in London, the United Kingdom. | Commercial Services |
Speedel Holding AG
Speedel Holding AG Pharmaceuticals: MajorHealth Technology Speedel Holding operates as a holding company with interests in pharmaceutical manufacturing. The company was founded on July 19, 2000 and is headquartered in Basel, Switzerland. | Health Technology |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Health Technology |
Lifearc
Lifearc Miscellaneous Commercial ServicesCommercial Services Lifearc provides research services. It specializes in intellectual property management, drug discovery, medical diagnostics and antibody engineering. The firm services include complete technology transfer service for scientists in MRC units and institutes, Awards to Inventors, Collaborative drug discovery and antibody engineering, Funding early stage research with commercial/translational potential and protecting new ideas. The company is headquartered in London, the United Kingdom. | Commercial Services |